The European Association of Urology (EAU) Neuro-Urology Guidelines aim to provide information for clinical practitioners on the incidence, definitions, diagnosis, therapy, and follow-up of neuro-urological disorders.
InVivo Therapeutics Holdings Corp. a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI),announced topline results from the company's INSPIRE 2.0 tudy, which was designed to evaluate the safety and probable benefit of InVivo's investigational Neuro-Spinal Scaffold, a bioresorbable scaffold-based device in development for patients with acute SCI.
Day One Biopharmaceuticals, Inc , announced that the FDA has approved Ojemda (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory BRAF-altered pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation
Insightec has submitted a pre-market approval application (PMA) to the FDA for its Exablate Neuro MRI-guided focused ultrasound surgery (MRgFUS)...
INSIGHTEC announced that the New England Journal of Medicine (NEJM) has published the results of a pivotal study of their...
The EU has awarded the ExAblate Neuro System, from InsighTec, the European CE mark for the treatment of neurological disorders...
Siemens Announces FDA Clearance of SMS, GOBrain Neuro MRI Applications. Siemens Healthcare has announced that the FDA has cleared two...
Ionis Pharmaceuticals, Inc. announced that the Phase III NEURO-TTR study of inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP)...
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. announced new long-term, open-label extension (OLE) data...
Sudden unexpected death in epilepsy (SUDEP) is the major cause of epilepsy-related premature mortality which targets preferentially younger people. Its etiology remains unknown. Several risk factors have been identified with...